Grace Therapeutics Inc. reported a net loss of $0.9 million for the three months ended September 30, 2025, a decrease of $2.5 million from a net loss of $3.4 million for the same period in 2024. Research and development expenses were $0.6 million, down from $3.0 million, mainly due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety trial. General and administrative expenses increased slightly to $2.0 million from $1.9 million, primarily due to pre-commercial planning costs for GTx-104. Cash and cash equivalents as of September 30, 2025, were $16.9 million, a decrease of $5.2 million from March 31, 2025. In October 2025, the company received $4.0 million from exercises of common warrants. Key business developments included FDA acceptance for review of the New Drug Application for GTx-104, with a PDUFA target date set for April 23, 2026, and the presentation of Phase 3 STRIVE-ON trial data.